Acetylcholine challenge produces M 3 muscarinic acetylcholine receptor activation and accessory/ scaffold proteins recruitment into a signalsome complex. The dynamics of such a complex is not well understood but a conserved NPxxY motif located within transmembrane 7 and juxtamembrane helix 8 of the receptor was found to modulate G protein activation. Here by means of receptor mutagenesis we unravel the role of the conserved M 3 muscarinic acetylcholine receptor NPxxY motif on ligand binding, signaling and multiprotein complex formation. Interestingly, while a N7.49D receptor mutant showed normal ligand binding properties a N7.49A mutant had reduced antagonist binding and increased affinity for carbachol. Also, besides this last mutant was able to physically couple to Gα q/11 after carbachol challenge it was neither capable to activate phospholipase C nor phospholipase D. On the other hand, we demonstrated that the Asn-7.49 is important for the interaction between M 3 R and ARF1 and also for the formation of the ARF/Rho/βγ signaling complex, a complex that might determine the rapid activation and desensitization of PLD. Overall, these results indicate that the NPxxY motif of the M 3 muscarinic acetylcholine receptor acts as key conformational switch for receptor signaling and multiprotein complex formation.
Introduction
The M 3 muscarinic acetylcholine receptor (M 3 R) is a member of the muscarinic receptor family that controls a large array of functions in both the central and peripheral nervous systems [1] . It is a class A, rhodopsin-like, G protein-coupled receptor (GPCR) that signals through the heterotrimeric G protein Gα q/11 , thus activating phospholipase C β (PLC β ) and increasing intracellular calcium [2] . M 3 R regulates a network of signaling molecules, including protein kinase C (PKC), small Rho GTPase, phospholipase D (PLD), phosphoinositide-3 1010 kinase (PI3K), non-receptor kinases and mitogenactivated protein kinases (MAPKs) [3] .
Interactions within conserved residues in the M 3 R intracellular loops have been proposed to be critical in preserving normal receptor activation, G protein-coupling, signaling and trafficking [4] [5] [6] . Chimeric receptor construction together with site directed mutagenesis showed that both the M 3 R second intracellular loop and the C-terminal portion of the third intracellular loop are important for coupling to the Gα q/11 protein [7] . In addition, receptor activation is mediated by a conformational rearrangement that includes transmembrane helix 7 (TMH7) and probably, as described for rhodopsin, movement within the C terminal tail juxtamembrane helix 8 (HX8) [8] .
Sequence alignment of GPCRs of the rhodopsin subfamily reveals that most members of this subfamily, including the M 3 R, contain a widely conserved NPxxY sequence motif at the end of TMH7 [9] . Interestingly, by means of mutagenesis and molecular modeling studies based on the rhodopsin crystal structure it has been shown that this motif is involved in an interaction network that modulates receptor's expression, signaling and trafficking [10] [11] [12] [13] [14] . Also, based on computational studies a theoretical model that explains the special structural features of the conserved N/DP motif has been proposed. Hence, this motif differs from a regular proline kink (of an ideal α-helix), thus allowing for a major flexibility in the TMH7 [15] . Consequently, by acting as a sensitive conformational switch this NPxxY motif may play a key role in the GPCR activation selectivity and efficacy, thus determining the receptor signaling extend. In addition, this domain regulates the interaction of the receptor with accessory/ scaffold proteins, thus controling the formation of the receptor signalosome. Indeed, interaction between M 3 R and small monomeric G proteins, for instance ADPribosylation factors (ARFs) and Ras homolog gene family member A (RhoA), has been described as critical during the activation of the PLD and ROCK pathway [16] [17] [18] [19] . Thus, based on the fact that NPxxY motif is involved in the activation and signalsome complex formation of some GPCRs we wanted to know the precise function of this motif in the M 3 R. Therefore, two mutants were generated, namely the Asn at position 540 (N7.49) and located within the conserved NPxxY motif was replaced by Asp (N7.49D) and by Ala (N7.49A). Mutation of Asn, to Ala switches the M 3 R to a high affinity inactive conformation unable to signal properly. However, the mutated receptor keeps the ability to form stable complexes with Gα q/11 protein in response to agonist-stimulation, as demonstrated by means of co-immunoprecipitation experiments. On the other hand, the N7.49D mutant (M 3 R N7.49D ) showed a unlike activation time-course and desensitization profile when compared to the M 3 R wt . Also, by means of coimmunoprecipitation experiments we corroborated that this mutant uses a non ARF1-mediated pathway to activate/desensitize the PLD. Overall, we showed that the conserved Asn residue within the NPxxY motif of the M 3 R determines the ability to form stable complexes with different populations of G proteins (Gα q/11 and Gα 12/13 ) and small monomeric G proteins (ARF1, ARF6 and RhoA), thus determining the activation/desensitization profile of the signaling pathways in which this receptor partake.
Materials and Methods

Materials
Dulbecco's modified Eagle's medium, penicillin/ streptomycin and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA, USA). [ 
Plasmid constructs
The constructs presented here were made using standard molecular biology techniques employing PCR and fragment replacement strategy. The cDNAs for the human M 3 R (kindly provided by T. Bonner, NIH, USA) was subcloned into the mammalian expression vector pcDNA-3.1 (Invitrogen) containing three hemagglutinin (HA) epitopes (pcDNA3.1-3xHA; gift from P. Calvo, SFU, CA, USA), thus resulting in the pcDNA3.1-3xHA-M 3 R vectors. Briefly, 1.9-kb fragment encoding the human M 3 R was amplified using sense and antisense primers harboring unique EcoRV and XbaI sites and then subcloned into EcoRV/XbaI sites of the mammalian pcDNA3.1-3xHA vector. The Asn of the M 3 R NPxxY motif was exchange to Asp and Ala by using the QuikChange site directed mutagenesis kit from Stratagene (La Jolla, CA, USA). The sense primers used were: FM 3 R N7.49D (5'-ACC TCT CTG GCT GTC CTA CTC ACC-3'); FM 3 R N7.49A (5'-CTG TTT CTG CTG GGC CCC CGC CTT TG-3'). The cDNA encoding the human GPR37 receptor was purchased from GenomeCube® (imaGenes, Berlin, Germany), amplified and subcloned into pcDNA-3.1. The reading frame, PCR integrity of the cloned constructs and the sequences of the mutants were confirmed by DNA sequencing. Finally, amino-acid residues along the human M 3 R sequence were numbered according the most conserved residue in the TMH and thus following the consensus-numbering scheme described by Ballesteros et al. [20] .
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Cell culture and transfection COS-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS), 100 U/ml streptomycin, 100 µg/ml penicillin, 2 mM L-glutamine (all from Invitrogen) at 37°C in a humidified 5% CO 2 incubator. For transfection, 2×10 6 cells were seeded into 100-mm dishes. About 24 h later, cells were co-transfected with pcDNA3.1-3xHA-M 3 R vector or mutants, by using the Lipofectamine TM Plus reagent (Invitrogen).
RNA Interference and immunofluorecence analysis
A pool of six different double-stranded siRNAs targeting ARF-1 were designed by and obtained from Santa Cruz Biotechnology (sc-141186, Stockholm, Sweden) and Selleck (ARF1 siRNA kit, TX, USA). A siRNA duplex with an irrelevant sequence (siRNA negative control, Selleck, TX, USA) was used as a control. Thus, COS-7 cells were transfected with 20 µM siRNA using Oligofectamine (Invitrogen) according to the manufacturer's instructions and transfection was repeated 24h later. Then, the next day cells were challenged with CCh at the indicated times and processed for ARF1 immunostaining and PLD activity determinations. In brief, for ARF1 immunostaining cells were labelled with the rabbit anti-ARF1 monoclonal antibody (Abcam, Stockholm, Sweden) and then a secondary antirabbit antibody coupled to Alexa-Fluor 488 (Molecular Probe, Stockholm, Sweden). Immunofluorescence analysis was carried out by using a 63× oil immersion objective in a Leica TCS-SL confocal microscope (Leica, USA). Images obtained from ten cells (two different experiments) were analyzed for each condition (control and ARF-1 depleted cells in 0, 15, 30 min CCh treated cells). For each image the average fluorescence intensity per field was examined.
Membrane preparation and radioligand binding assay
About 48 h after transfection, COS-7 cells were washed twice with cold phosphate-buffered saline (PBS; pH 7.4), harvested and homogenized in binding buffer (25 mM sodium phosphate, 5 mM MgCl 2 , pH 7.4), using a Polytron tissue homogeniser. Cell membranes were collected by centrifugation at 20000xg for 15 min and homogenized as above. After centrifugation at 40000xg for 20 min at 4°C, the final pellet was resuspended in binding buffer, and membranes were either used immediately or frozen in liquid nitrogen and stored at -80°C until needed. Protein concentration was determined by using the Bradford protein assay kit (Bio-Rad, Hercules, CA, USA). To determine the affinity of NMS for each sample, membranes were incubated with different concentrations of [ Agonist binding studies were carried out without GTP and GTP analogues; because previous studies had shown that such agents did not affect the agonist binding properties of the M 3 R when transiently expressed in COS-7 cells [21] . Assays were stopped by filtration and samples were subject to scintillation counting, as described above. 2 , and 5Mm Dglucose, pH 7.4). Then, agonist was added in the conditions described above for the indicated periods of time. Inhibitory agents and the butan-1-ol were added 30 min before and immediately after agonist addition, respectively. For assays in acute permeabilized cells, prelabeled COS-7 cells were incubated with agonist (100 µM CCh) or vehicle for 10 min at 37°C before intracellular buffer was added (2 mM MgATP, 10 µM NAD, 8 µM digitonin, and 30 mM butan-1-ol) in the presence or absence of Brefeldin A (BFA) or C3 exoenzyme (C3). Data from scintillation counting of 4 to 6 independent experiments were expressed as means ± S.E.
PLD and PLC assay activities
When indicated, PLD activity was also evaluated by the Amplex Red Phospholipase D assay kit (Molecular Probes, Stockholm, Sweden) used according to the manufacturer's instructions. Briefly, transiently transfected COS-7 cells were washed 3 times with phosphate-buffered saline and then incubated overnight in basal medium containing 5 mg/mL bovine serum albumin (BSA) and antibiotics. Cells were challenged with CCh (10 µM) during 15 and 30 min. The basal level of constitutive PLD activity was determined in the absence of CCh. Next, cells were washed with and kept in 300 µL with ice-cold 50 mM Tris, pH 8.0, containing 1 mM EGTA and complete protease inhibitor cocktail without ethylenediaminetetraacetic acid (Roche, Stockholm, Sweden). Cells were lysed by 3 freeze-thaw cycles, collected and mixed 1:1 (v/v) with Amplex Red reaction buffer (Amplex Red Phospholipase D assay kit; Molecular Probes), and PLD activity was measured as a fluorescence signal after 30 minutes incubation at 37°C in a POLARstar Optima plate reader (BMG Labtech, Offenburg, Germany). 1 nM to 1 mM) . The reaction was stopped by addition of 5 ml of ice-cold buffer containing 10 mM HEPES/NaOH, 1 mM MgCl 2 , pH 7.4 followed by rapid filtration through glass fibre filters GF/C filters (Whatman) presoaked in the same buffer. The filters were washed twice with 5 ml of ice-cold buffer and the radioactivity was measured by scintillation counting. Nonspecific binding was determined in the presence of 10 µM GTPγS. Assays were performed in triplicate.
Co-immunoprecipitation and Western blot experiments
Immunoprecipitation and western blot experiments were carried out as described previously [23] . Briefly, to immunoprecipitate M 3 R constructs and its associated proteins, plasmids encoding the 3xHA-M 3 R constructs and the Gα q/11 , Gα 12/13 , RhoA GFP , ARF1 GFP or ARF6 GFP expressing vectors were transiently co-transfected into COS-7 cells. After 48 h cells were serum-deprived for 4 h and then incubated in the absence or presence of 10 µM of CCh for 10 min. After a washing with cold PBS the cells were solubilized with 4 mM CHAPS and processed for immunoprecipitation using a mouse anti-HA monoclonal antibody (A01244, 1 µg; Genscript, Hong Kong). Proteins transferred onto PVDF membranes were immunodetected by using a goat anti-HA polyclonal antibody (A00168, 1:1000; Genscript), rabbit anti-Gα q/11 polyclonal antibody (sc-392, 1:1000; Santa Cruz Biotechnology), rabbit anti-Gα 12/13 polyclonal antibody (s-20, 1:300; Santa Cruz Biotechnology) and rabbit anti-GFP polyclonal antibody (A01388, 1: 10000; Genscript) as primary antibodies; and then horseradish-peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:60000; Pierce, Rockford, IL, USA) and horseradishperoxidase (HRP)-conjugated mouse anti-goat IgG (1:30000; Pierce) as secondary antibodies, and developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
MAPK assay
Transiently transfected COS-7 cells expressing M 3 R subtype were grown to 80% confluence and rendered quiescent by serum starvation overnight before MAPK phosphorylation assay. Subsequently, further 2h incubation in fresh serum-free medium was performed to minimize basal activity. Then, cells were stimulated by adding medium containing the muscarinic agonist CCh (10 µM). Rapid rinsing, with ice-cold PBS finished stimulation, and cell lyses was performed during 10 min by adding 500 µl ice-cold lyses buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% TritonX-100, protease and phosphatase inhibitor cocktail). The cellular debris was removed by centrifugation at 13000xg for 5 min at 4°C, and the total protein content was measured using BCA Protein Assay Reagent (Pierce). Aliquots corresponding to 5 µg of protein were mixed with sodium dodecyl sulphate (SDS) loading buffer, applied to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western blot. Extracellular signal regulated kinase 1/2 (ERK1/2) activation was assayed by incubating PVDF blots with a mouse anti-phospho-ERK1/2 monoclonal antibody (Sigma-Aldrich). Control blots were also run in parallel and probed with rabbit anti-ERK1/2 polyclonal antibody (SigmaAldrich) that recognized both unphosphorylated and phosphorylated forms. The immunoreactive bands were visualized as described above and then measured by quantitative densitometry.
Data analysis
All binding data were analyzed using the GraphPad PRISM 4.0 software (GraphPad Prism, San Diego, CA, USA). Basal binding was defined as [ 
Results
In order to unravel the structural and functional role of the M 3 R NPxxY motif we performed mutagenesis experiments. Thus, the Asn of this conserved domain along muscarinic acetylcholine receptors ( Fig. 1 ) was replaced by aspartic acid (Asp; N7.49D) and by alanine (Ala; N7.49A). Subsequently, agonist and antagonist binding determinations, phosphoinositide hydrolysis stimulation, G protein activation and coimmunoprecipitation experiments with monomeric small and heterotrimeric G proteins were performed after transient expression of these receptor constructs into COS-7 cells. showed a ~7.6 fold-increment in affinity, thus suggesting that the Asn→Ala substitution increases the affinity of the receptor for carbachol.
Ligand binding properties of the NPxxY motif mutants
is unable to activate the PLC, the PLD and the MAPK pathway Next, we explored the functionality of each receptor mutant expressed in COS-7 cells by quantifying the activation of the main signaling pathways activated by the M 3 R, namely the PLC, the PLD and the MAPK pathway [3] . M 3 R-mediated PLC stimulation has been extensively described and constitutes one of the main pathways activated by this muscarinic acetylcholine receptor subtype after agonist challenge [24, 25] . In order to assess the ability of wild type and mutant receptors to activate the PLC-signaling cascade, we measured the total inositol phosphates (IP) accumulation. As expected, the M 3 R wt stimulation produced a dose-dependent accumulation of IP with an EC 50 of 3.4±0.5 µM (Fig.  2A) . Also, the M 3 R N7.49D
showed a similar dose-response curve of IP accumulation (EC 50 =3.6±0.2 µM; Fig. 2A) . Interestingly, under similar experimental conditions no significant agonist-mediated IP accumulation was observed in cells expressing the M 3 R N7.49A ( Fig. 2A) . Although the most established M 3 R signaling pathway is the pertussis toxin-insensitive activation of PLC via the heterotrimeric Gα q/11 protein, PLD is also strongly activated via both the Gα q/11 and Gα 12/13 proteins [26, 27] . We then studied the ability of the M 3 R was unable to activate PLD even when exposed to 1 mM of CCh (Fig. 2B) . Finally, to rule out that the measured EC 50 and E max changes were due to changes in receptor density we plotted the negative logarithm of EC 50 vs. the M 3 R wt and M 3 R N7.49D
density. This plot showed that while the receptor expression could be slightly variable the EC 50 shift was independent of receptor density (data not shown).
The M 3 R NPxxY Motif . Results represent mean ± S.E. (n = 5). Next, we decided to test whether the M 3 R mutations impinge into the receptor-mediated MAPK pathway activation. It is well-known that M 3 R can activate the MAPK pathway by two ways one that is dependent of protein kinase C and the other independent [28, 29] . Thus, we first assessed whether the M 3 R and serum deprived for 12 h before adding CCh (10 µM) for 5 min. Then, cells were washed and processed for MAPK phosphorylation assay (see Materials and Methods). Unphosphorylated and phosphorylated p42 and p44 MAPKs forms were detected using a rabbit anti-ERK1/2 polyclonal antibody and a mouse anti-phospho-ERK1/2 monoclonal antibody, respectively. Immunoreactive proteins were detected using a horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescences. The intensity of the bands was quantified was unable to trigger a significant ERK1/2 phosphorylation when compared to the other two constructs (Fig. 3) . [27] . Thus, it might be the case that this construct have a lesser affinity for G proteins and when transiently expressed in COS-7 cells it is unable to couple/activate the endogenous G proteins. Consequently, we proceed to coexpress our M 3 R constructs with Gα q/11 and Gα 12/13 in COS-7 cells and check for their functionality. In our hands, co-expression of both Gα q/11 or Gα 12/13 subunits with the M 3 R was co-expressed with either Gα subunits we did not observed PLC nor PLD activation, in agreement with our previous results (Fig. 2) . Besides that the M 3 R N7.49A did not activate PLC and PLD we wanted to explore if this receptor mutant was able to directly activate Gα proteins, thus we proceeded to check basal guanine nucleotide exchange, using a [ Arrows denote the plasma membrane distribution of ARF1. This figure is representative of the results obtained in two independent experiments. B. Quantitative ARF-1 immunofluorescence defined as the average fluorescence intensity in a constant field. The data represent the mean ± S.E. of 2 independent experiments (ten images). Statistical significance was determined using Two way ANOVA (PRISM software) (***, p < 0.001). C. Agonist-induced PLD activation in control or ARF1-depleted COS-7 cells. Cells, transiently expressing the M 3 R, were treated with 10 µM of CCh for 15 and 30 min. The data represent the mean ± S.E. of three independent experiments. Statistical significance was determined using Two way ANOVA (PRISM software) (***, p < 0.001). challenge (10 µM of CCh) promoted the interaction of the receptor with the G protein as a band that migrated at 42 kDa corresponding to the Gα q/11 was clearly coimmunoprecipitated using an antibody against the receptor (Fig. 4) to the Gα 12/13 was observed (Fig. 4) . Interestingly, this basal association with the Gα 12/13 protein was unaltered by agonist challenge in the cells expressing the M 3 R and challenged with CCh (Fig. 4) . Under these experimental conditions the M 3 R N7.49A did not show any association with the Gα 12/13 even after agonist challenge (Fig. 4) . Overall, these results demonstrated that the M 3 R N7.49A associated with Gα q/11 in a similar way as to the M 3 R wt , however this association was not sufficient to activate it, thus suggesting that Asn-7.49 is specifically involved in the M 3 R-mediated Gα q/11 protein activation. Also, the Asn→Asp substitution within the NPxxY promoted the association of M 3 R wt to Gα 12/13 .
The Asn-7.49 plays a key role in the agonistmediated receptor association with and signals by small monomeric G proteins
In order to elucidate the role of Asn-7.49 in the mechanism of M 3 R signaling through small monomeric G proteins we performed coimmunoprecipitation experiments with the ARF and RhoA proteins as these have been described to partake in the receptor signal transduction [16, 18, 19, 30] . Consequently, in cells cotransfected with the M 3 R wt and RhoA GFP the agonist challenge promoted the receptor-RhoA interaction as a band that migrated at 50 kDa corresponding to the RhoA GFP was coimmunoprecipitated using an antibody against the HA tag present in all the M 3 R constructs (Fig.  4) (Fig. 4) . plus ARF6 the agonist treatment was unable to promote the association of these receptor constructs with ARF6 (Fig. 4) . Finally, no coThe M 3 R NPxxY Motif immunoprecipitation of these small G proteins was observed when an HA untagged GPR37 receptor was used in our experiments as a control (Fig. 4, Mock) . Collectively, our coimmunoprecipitation experiments allowed us to show that ARF1 and ARF6 are constitutively associated with the M 3 R and that the carbachol challenge promoted the coupling of RhoA and ARF1 with the receptor. Overall, it can be concluded that ARF1 is switched to Gα 12/13 as NPxxY is mutated to DPxxY.
Next, we pharmacologically characterized the agonist-mediated PLC and PLD activation in COS-7 cells expressing M 3 mediated PLC activation was equally blocked by the U73122, an inhibitor of PLC-dependent processes [31] (Fig. 5A) . Interestingly, the M 3 R wt and the M 3 R N7.49D -mediated PLC activation was not inhibited by brefeldin A (BFA), an inhibitor of guanine-nucleotide exchange in ARF [32] ; by C3 exoenzyme from Clostridium botulinum which inactivates Rho family members (i.e. RhoA) by means of covalent ADP-ribosylation [33] ; and by coexpression with the C-terminal tail of the GRK2, which acts as G protein βγ-subunit scavenger [34] (Fig.  5A) . These results demonstrated that the Asn→Asp substitution at the conserved NPxxY motif do not affect the PLC activation pattern. On the other hand, M 3 R wt -mediated PLD activation was sensible to BFA, to C3 exoenzyme and to the inhibitory G protein βγ peptide (Fig.  5B) . These results suggest that the small G proteins (e.g. ARF1/6 and RhoA) and the G protein subunits βγ are involved in the PLD activation, thus illustrating a crosstalk between heterotrimeric and monomeric G-proteins. Interestingly, the M 3 R N7.49D -mediated PLD activation was not blocked by either BFA, C3 exoenzyme or the inhibitory G protein βγ peptide (Fig. 5B) , thus suggesting that the Asn-7.49 play a key role in the ARF/Rho/βγ subunitmediated PLD activation. Overall, these results agree with the current notion that during agonist activation the M 3 R suffers a conformation change that allows the selective translocation/activation of ARF1/RhoA/βγ subunit to the plasma membrane and thus promoting the activation of PLD and controling the PLD desensitization process.
To further confirm the role of ARF1 in the M 3 Rmediated PLD activation, we studied PLD activity in ARF1-deficient cells. To this end, a pool of six different double-stranded siRNAs targeting ARF-1 was used to knock down the ARF1 expression in COS-7 cells. Firstly, by means of immunofluorescence and confocal miscroscopy observations we confirmed that the transfection Borroto-Escuela/Romero-Fernandez/García-Negredo/Correia/Garriga/ Fuxe/Ciruela of the ARF1 siRNA, but not the control siRNA, largely reduced (~85%) the ARF1 expression in COS-7 cells (Fig. 6A-B) . In addition, when the subcellular distribution of ARF1 was analyzed in control cells (transfected with the control siRNA) we found mostly a cytosolic distribution of the ARF-1 protein that was almost undetectable in ARF1 siRNA transfected cells (Fig. 6A) . Interestingly, when cells were challenge with CCh the ARF1 protein showed a more plasma membrane/cytosolic subcellular distribution (Fig. 6A) which again was almost undetectable in cells transfected with ARF1 siRNA (Fig. 6A) . In addition, it is noticeable that CCh incubation promoted a marked change in the cellular shape, probably as result of a cell cytoskeleton rearrangement (Fig. 6A) , as it has been previously demonstrated [35] . Indeed, a canonical Rho-mediated cytoskeletal rearrangement has been described [36] . Next, under these experimental conditions (i.e. ARF-1 siRNA transfection) we assessed the ability M 3 R to activate PLD after agonist challenge. Thus, transiently transfect COS-7 cells were incubated with 10 µM CCh for 15 and 30 min and the PLD activity measured. Interestingly, the activation of PLD following CCh stimulation was dramatically reduced in the cells cotransfected with the ARF-1 siRNA (Fig. 6C) . However, when cells were cotransfected with the control siRNA a significant increased in the PLD activity was observed after 15 and 30 min of CCh incubation (Fig. 6C) . Overall, these data further support the idea that ARF1, probably at the plasma membrane, specifically regulates M 3 Rmediated PLD activation. to 1 mM of CCh induced an acute sensitization of the receptor-mediated PLC activation (~6 fold over the basal after 1 hour of the initial 2 min agonist challenge), as previously described in HEK cells [22] . Overall, no obvious differences in the PLC The M 3 R NPxxY Motif activation time-course and desensitization profile between the M 3 R wt and the M 3 R N7.49D
were observed. Next, we performed time-course experiments of receptor-mediated PLD activation. Thus, the M 3 R wt showed a pattern of PLD activation with a maximal peak after ~5 min of agonist incubation, followed by a stable plateau (Fig. 7B, left panel) . Interestingly, the M 3 R N7.49D
showed an unlike PLD activation profile that was more similar to that observed for the activation of PLC, thus reaching a maximal peak between 40 to 60 minutes after agonist exposure (Fig. 7B, left panel) . On the other hand, a 2 min agonist preexposure of the M 3 R wt induced a rapid and persistent desensitization of the receptor-mediated PLD activation (Fig. 7B, right panel) , as previously described [22] . Interestingly, the M 3 R N7.49D
showed a PLD desensitization profile more similar to the one observed for the PLC, thus the 2 min agonist preexposure induced an acute sensitization of the receptor-mediated PLD activation (~4 fold over the basal after 30 min) ( lacks the carbacholmediated receptor-ARF1 association it could be proposed that the fast activation and fast desensitization of the M 3 Rmediated PLD activation is ARF1 dependent (Fig. 8) . Therefore, it might be speculated that M 3 R wt can activate PLC and PLD through a signaling complex (e.g. Gα q/11 / Gα 12/13 /ARF1/RhoA/βγ subunit) that might be different to that used by the M 3 R N7.49D
. Overall, the Asn→Asp substitution at the conserved NPxxY motif determines the receptor-G protein switching mode and specificity of the effector activation (e.g. PLC and PLD).
Discussion
Sequence alignment of class A GPCRs reveals that most of its members contain the NPxxY motif [37] . Interestingly, mutagenesis experiments along this domain have been shown to affect the receptor's ligand affinity, expression, G protein-coupling, association with small G proteins and endocytosis [10] [11] [12] [13] 38] . As the M 3 R also contains this NPxxY motif at the end of it seven transmembrane domain ( Fig. 1) we wanted to know the precise role of this motif in receptor functioning.
Consequently, to address this question we used site direct mutagenesis in combination with coimmunoprecipitation experiments and signal transduction assays. Thus, this study demonstrates for the first time that the Asn-7.49 of the M 3 R NPxxY motif plays a key role in the carbacholmediated ARF1 association and PLD activation.
Our results are in line with previous studies demonstrating that some residues located within transmembrane helix 7 of certain GPCRs while not being directly implicated in ligand-binding they are involved in the receptor signal transduction. Indeed, during the agonist-mediated conformational rearrangement the residues forming the NPxxY motif are key positions in hydrogen bound formation through receptor stabilization [12, 39, 40] . In our hands, in the M 3 R the Asn→Ala substitution (N7.49A point mutation) resulted in a significant decrease in the antagonist maximum binding capacity and an increase in the agonist affinity. A potential explanation would be that the nature of the physicochemical change involved in Asn to Ala mutation somehow affects the hydrogen bond formation essential for keeping the receptor in a stable conformation during activation. Interestingly, Ala replacement at position N7.49 in rhodopsin and in the formyl peptide receptor (FPR) while not promoting a conformational reorganization of the active state of the receptor it implicated a variable change in agonist/antagonist affinity when compared to the wild type receptor [10, 12] . On the other hand, the M 3 R Asn→Asp substitution (N7.49D point mutation) did not affect the agonist/antagonist binding properties of the receptor, thus suggesting that this change in charge did not affect the receptor ligand binding properties. In addition, the N7.49A/D M 3 R mutants provided further information concerning the receptor's downstream signal transduction. Thus, while the N7.49D point mutation did not affect the affinity and efficacy of the receptor-mediated PLC and PLD activation the N7.49A one precluded the receptor to activate both phospholipases. A comparable functional result was observed when the MAPK pathway was analyzed, thus the M 3 R N7.49A mutant was unable to elicit a significant ERK1/2 phosphorylation. Overall, while the change of Asn by Asp maintains a relatively stable conformation of the receptor and does not substantially perturb the conformational change produced during receptor activation the Asn→Ala substitution precluded the receptor-mediated signal transduction.
Our coimmunoprecipitation studies with monomeric small and heterotrimeric G proteins grant some insight about the M 3 R signal transduction mechanism. First, we showed that M 3 R constitutively associated with Gq /11 , ARF1 and ARF6 (Fig. 4) and that agonist challenge promoted the coupling of Gα q/11 , RhoA and ARF1 with the receptor (Fig. 8) . In addition, the M 3 R wt -mediated PLC activation was inhibited by U73122 and the PLD activation by BFA, by C3 exoenzyme and by a G protein βγ-subunit scavenger. Hence, a major signal transduction complex containing Gα q/11 , ARF1, RhoA and G protein βγ-subunit was depicted (Fig. 8) . Next, when the Asn-7.49 of the M 3 R NPxxY motif was substituted for Ala (N7.49A point mutation) despite a constitutive faint basal association with ARF1/6 and an agonist-promoted Gα q/11 coupling was observed the M 3 R N7.49A was unable to associate to Gα 12/13 and to RhoA, and thus to activate both PLC and PLD. Finally, the Asn→Asp substitution although did not affect the agonist-mediated receptor association with Gα q/11 and RhoA it precluded the agonistmediated receptor-ARF1 association and favored the Gα 12/13 coupling. Interestingly, this unusual receptor coupling pattern did not affect to the PLC activation but it had a profound effect on the PLD stimulation, thus being now insensitive to the G protein βγ-subunit scavenger and to the monomeric small G proteins inhibitors (e.g. BFA and C3 exoenzyme). In addition, our coimmunoprecipitation experiments clearly demonstrated that the N7.49D mutant retains an intact capacity to form stable complexes with RhoA in response to CCh (Fig. 4) , thus the formation of high affinity M 3 R-RhoA complexes is not sufficient to activate PLD in a RhoA-dependent manner (Fig. 5B, right  panel) , and consequently, it can be assumed that RhoA is not involved in the M 3 R N7.49D -mediated PLD activation. Overall, the Asn-7.49 of the M 3 R NPxxY motif is specifically involved in the CCh-mediated ARF1 association and in the RhoA-mediated PLD activation.
Previous studies reported that a N376 to D mutation in the conserved NPxxY motif of the 5-HT 2A receptor alters the coupling preference from ARF1 to ARF6 [14, 41] . These data suggest that the presence of the N or a D in this highly conserved motif is an important, but not exclusive, determinant of which ARF isoform interacts with the GPCR, since some NPxxY motif-containing receptors such as the M 3 R used both isoforms. Our results partially agree with these as the presence of Asp in the M 3 R DPxxY motif did not promote the coupling to ARF6, as happens for other receptors, but precluded the agonistmediated association with ARF1. Interestingly, it has been nicely demonstrted that mutation of the Asn-7.49 of the conserved NPxxY motif of the cholecystokinin B receptor (CCKBR) abolishes Gα q/11 protein activation without affecting its association with the receptor [11] . In brief, the mutated CCKBR retains an intact capacity to form stable complexes with Gα q/11 subunits in response to CCK but it was completely unable to mediate activation of either phospholipase C and protein kinase C-dependent andindependent mitogen-activated protein kinase pathways [11] , thus indicating that the formation of high affinity CCK-receptor-Gα q/11 protein complexes is not sufficient to activate Gα q/11 and suggest that while the Asn-7.49 is specifically involved in Gα q/11 protein activation other residues might be involved in Gα q/11 binding [11] . Similarly, we described here that the Asn→Asp substitution within the M 3 R NPxxY motif did not affect the association with RhoA but it precluded the small G protein-dependent PLD activation, thus it can be hypothesized that either other residues different than Asn-7.49 might participate in the M 3 R-RhoA interaction or that other proteins that act as adapters or regulators of small G protein function may participate or mediate in the association with the receptor. Thus, future studies devoted to clarify the nature of this interaction will determine if RhoA and M 3 R interact directly to activate RhoA or if the complex involves other proteins (i.e. ARFs, etc.). Overall, we identified here a single residue within the M 3 R sequence that appears to act as a molecular switch for receptor-mediating RhoA activation.
It has been shown that agonist challenge of the M 3 R leads to activation of both PLC and PLD but with distinct efficacies and stimulation/desensitization time-courses [22] . However, the essential transducing elements responsible for this differential stimulation/desensitization pattern were not fully identified. Also, it has been demonstrated that the M 3 R substantially used an ARF-dependent pathway for PLD activation [30] . Thus, the M 3 R displayed a major ARF1-dependent route for PLD1 activation, whereas the ARF6-dependent pathway activates both PLD1 and PLD2 [30] . Nonetheless, the role of ARFs proteins in the M 3 R-mediated desensitization of these phospholipases has not been unraveled yet. Our results demonstrated that the Asn-7.49 is essential for grip the M 3 R-mediated PLD fast activation and long-lasting desensitization observed in our experiments and also previously reported [22] . This long-lasting M 3 R-mediated PLD desensitization suggests that either an inhibitory factor is formed upon receptor activation or that the activated receptor induces the loss or permanent inactivation of an essential coupling component. Indeed, our results also suggest that the Asn-7.49 is necessary for the carbacholmediated ARF1-receptor association. Thus, we can conclude that the M 3 R-mediated PLD fast activation and long-lasting desensitization is ARF1 dependent (Fig. 8) . Finally, some members of the GPCR family receptors Cell Physiol Biochem 2011;28:1009-1022
